Of 320 patients with metastatic malignant non-seminomatous germ cell tumours of the testis (NSGCT) treated with chemotherapy, 266 (83%) are alive and well after a median follow-up of 39 months. Deaths from treatment-related causes occurred in 9 patients and were related to intensity of chemotherapy. Relapse after chemotherapy was rare except in presentations with large tumour volume and high serum marker concentrations and a strategy has been developed of risk-related choice of chemotherapy in order to reduce treatment toxicity in good prognosis sub-groups of patients.
No takes yet. Share an insight, caveat, or question.
Peckham et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: